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Abstract
Background: Aim of this study was to verify a systematic and practical categorization system that allows dynamic
classification of pediatric DPLD irrespective of completeness of patient data.
Methods: The study was based on 2322 children submitted to the kids-lung-register between 1997 and 2012. Of
these children 791 were assigned to 12 DPLD categories, more than 2/3 belonged to categories manifesting
primarily in infancy. The work-flow of the pediatric DPLD categorization system included (i) the generation of a final
working diagnosis, decision on the presence or absence of (ii) DPLD and (iii) a systemic or lung only condition, and
(iv) the allocation to a category and subcategory. The validity and inter-observer dependency of this workflow was
re-tested using a systematic sample of 100 cases.
Results: Two blinded raters allocated more than 80 % of the re-categorized cases identically. Non-identical allocation
was due to lack of appreciation of all available details, insufficient knowledge of the classification rules by the raters,
incomplete patient data, and shortcomings of the classification system itself.
Conclusions: This study provides a suitable workflow and hand-on rules for the categorization of pediatric DPLD.
Potential pitfalls were identified and a foundation was laid for the development of consensus-based, international
categorization guidelines.
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Background
Childhood interstitial lung diseases (ILD) represent a large
spectrum of individually rare diffuse parenchymal lung
diseases (DPLD), prevalent in children of all ages [1–3].
They comprise more than 200 different disease entities
which are treated by pediatricians and general practitioners
in general and specialized (children´s) hospitals. Due to the
similarity of symptoms it is often difficult to differentiate
these rare patients from children with more common re-
spiratory diseases [4]. Clinical presentation of the disease
may further be blurred by recurrent infections or allergies.
Childhood DPLD may thus easily be underdiagnosed.
Correct classification of all patients is however indispensable
for the appropriate treatment, for a better understanding of
the underlying pathophysiology, for the identification of bio-
markers and for long-term studies and cohort investigations.
Several categorization systems of childhood DPLD have
been proposed over time [1, 5–7]. The majority of the recent
systems are based on lung histology, related to the study by
Deutsch et al. [1], which classifies the broad spectrum of
patients into eight disease categories containing various
diagnoses [1]. The categorization system has in the mean-
time been expanded to the entire pediatric age range [6]
and has been shown useful for pathological studies [7]. In a
single center study the system was also used for cases not
diagnosed by biopsy [8].
Aim of this study was to verify a systematic and practical
categorization system that allows dynamic classification of
pediatric DPLD irrespective of completeness of patient data.
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The work-flow and validity of the categorization system was
tested, basis were all cases submitted to the kids-lung-register
(KLR) between 1997 and 2012 [2]. The kids-lung-register is,
an open, non-profit register for rare lung diseases in child-
hood and adolescence (www.kids-lung-register.eu). On aver-
age 147 children with lung diseases per year are referred to
the kids-lung-register for consultation and laboratory services
from diverse European centers. Based on the kids-lung-
register a European management platform was established in
2013 for childhood interstitial lung diseases (http://www.klini-
kum.uni-muenchen.de/Child-EU/en/index.html) comprising
10 academic partners from 5 European countries.
Methods
DPLD are entities originating from abnormalities of lung
interstitial tissue components. These structures in the per-
iphery of the lungs include the alveolar epithelium, the ves-
sel endothelium and the tissues between these structures.
More centrally they include peribronchiolar and peribron-
chial tissues [9]. Airways may be involved secondary in the
disease process. DPLD disorders more prevalent in infancy
(A) and disorders occurring at all ages (B) are differentiated.
Diseases which affect the parenchymal tissue, but are local-
ized gross structural abnormalities of the lungs, either con-
genital (C1) or acquired (C2) are not classified as DPLD.
Further separated are disorders which primarily affect the
airways (airway disorders (D)), the pleural tissues (pleural
diseases (E)), diseases caused by lung infections (F) or
neoplasms (G), which may also involve the parenchyma.
Workflow for patient categorization during routine
operation of the KLR
For the cases referred to the KLR the categorization system
for DPLD suggested by Deutsch et al. [1] was further
developed; three additional categories were introduced
(Additional file 1: Table S1) to accommodate cases with
“unclear respiratory distress syndrome” in the mature neonate
(Ax) and in the almost mature neonate (Ay) and “unclear
respiratory distress syndrome” in the non-neonate (By). These
categories allow the future analysis of unclear cases. In
addition, the rather wide category “disorders masquerading as
ILD” was dissolved into two more specific categories: “DPLD
related to lung vessels structural processes” (B4) and “DPLD
related to reactive lymphoid lesions” (B5) (Fig. 1).
Practical categorization rules were initially set up by the
KLR (Table 1) to assure consistent categorization. 2322
children were referred to the KLR between 1997 and
2012. DPLD was suspected in a child with (1) respiratory
symptoms and signs such as cough, tachy-/dyspnea at rest
or with exercise, crackles, retractions, digital clubbing,
failure to thrive, or respiratory failure, and (2) hypoxemia,
and (3) diffuse radiological abnormalities and (4) if feasible
Fig. 1 Overview on study design. The upper part (black) of the figure shows the patients collected in the kids lung register (KLR) and categorized
according to the KLR algorithm between 1997 and 2012. Patients received a working diagnosis and were categorized into DPLD categories and
subcategories; the latter process is described in more detail in Addditional file 2: Figure S1. The lower part of the figure (red) describes the workflow
used for the re-categorization of 100 cases selected randomly and in proportion of their occurrence in the KLR. Two reviewers (AI, MG) re-assessed
those cases blinded and independently and obtained a working diagnosis, categorization and sub-categorization according to the workflow in the
lower part of Addditional file 2: Figure S1 (red)
Griese et al. Orphanet Journal of Rare Diseases  (2015) 10:122 Page 2 of 6
Table 1 Rules for allocating a “final working diagnosis” to the disease categories and subcategories
General rules Examples
1. A final working diagnosis is established based on the available information
The final working diagnosis is the diagnosis with the highest likelihood.
Even if some diagnostic tests are missing or the information level is low,
a final working diagnosis is defined and used for categorization. Clinical
symptoms (cough, dyspnea, etc.) are only considered informative for
categorization if typical for the diagnosis
- Sarcoidosis is diagnosed based on chronic dyspnea, interstitial fine
nodules, granulomatous skin lesions in biopsy, and increased
angiotensin converting enzyme levels.
- Respiratory distress in the mature neonate as DPLD is diagnosed after
the exclusion of infectious, cardiac, metabolic, neurologic and localized
pulmonary causes.
- Tachypnoe in infants with NEHI
2. DPLD or not? Are any aspects of the final working diagnosis related to DPLD?
(a) Yes: the case should be categorized in the DPLD system - Child with juvenile myelomonocytic leukemia and dyspnea, cough and
reversible airway obstruction. On CT scan no evidence for obliterative
bronchiolitis and bronchiectasis.(b) No: no categorization in the DPLD system
⇨ Airway disease, no DPLD
- Same history with same findings, but on CT scan septal thickening and
centrilobular nodules
⇨ DPLD-in the immunocompromised host or transplanted (B3)
- Pneumonia in a patient with chronic granulomatous disease, no
evidence of an interstitial lung disease
⇨ systemic disease, no DPLD
3. Systemic or lung-only condition? Is the lung disease part of a systemic
disease process or is it a lung-only condition?
a) Allocation of a lung disease as part of a systemic disease process is
preferred over classifying as lung-only DPLD, if there is any evidence for
the involvement of systemic structures
- Clinical, BAL or histological evidence for pulmonary hemorrhage
without any evidence for systemic involvement, diagnosis of
idiopathic pulmonary hemosiderosis
Reason: it is more likely that the systemic disease causes a lung problem,
than that an independent rare lung disease emerges in addition to a
DPLD related to a systemic disease.
⇨ DPLD - related to lung vessels structural processes (B4)
Consequences:
- Pulmonary hemorrhage and a disease-causing mutation for Osler’s disease
⇨ DPLD - related to systemic disease processes (B1)
(i) same histological pattern may be present in different categories - Pulmonary hemorrhage and celiac disease
⇨ DPLD - related to systemic disease processes (B1)(ii) carefully re-evaluate for potential lung disease only
b) Allocation of a disease as a lung-only DPLD in the presence of hints
for the involvement of systemic structures should only be done if
convincing evidence supports a lung-only DPLD
- Acute lymphatic leukemia treated with chemotherapy and stem cell
transplant, development of pulmonary pathology, histologically NSIP
⇨ DPLD – related to systemic disease processes (B1): lung injury as a
complication or therapy more likely than independent lung disease
- Same history, but detection of two disease causing ABCA3 mutations in
the patient
⇨ DPLD – related to alveolar surfactant region (A4): lung-only DPLD in
addition to oncologic disease
4. Select a category and a subcategory which best accommodates the
final working diagnosis
Prefer the category/subcategory with
(a) a better causal link/explanation for the lung disease: cause of
pulmonary disease is for example ranked higher than the histological
pattern alone, since the same histological result can be allocated to
several categories. If the cause is not determinable, the most likely
association of the histological pattern with a disease is selected.
- a patient with a drug-induced hypersensitivity reaction of the lung and
the histological pattern of NSIP
⇨ DPLD - in the presumed immune intact host, related to exposures (B2)
- A patient with NSIP and no further clinical information
⇨ DPLD - related to the alveolar surfactant region (A4) is selected and
awaits further molecular characterization, as NSIP can be associated
with SFTPC, ABCA3, or TTF1/Nkx2.1 mutations
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and available, abnormalities in pulmonary function testing.
Minimum duration of symptoms was 4 weeks.
During capture of the cases with suspected DPLD the re-
ferring physician mostly specialized in pediatric pulmonol-
ogy on the level of a tertiary or university hospital diagnosed
the patients in cooperation with the radiologist and in cases
with biopsy the pathologist. Available material included a
clinical history, biochemical, radiological, histological and
genetic data of varying level of detail. A diagnosis was
independently also established by each of the KLR experts:
F. B., a pathologist; P. L. a geneticist; M. G., a pediatric
clinician and pulmonologist (Additional file 2: Figure S1).
A four-step algorithm was used for categorization
(Table 1): in a first step, a “final working diagnosis” was
defined by consensus discussion, entered into the data-base
and used for categorization and sub-categorization. In a sec-
ond step it was analyzed if the final working diagnosis was
related to DPLD. In a third step it was decided whether the
patient suffered from a lung only condition or if the lung
disease was part of a systemic disease. Of note, the latter are
not restricted to the diagnosis of category B1. Other organ
systems than the lungs may also be involved in diseases of
categories B3, B4, B5, A1 and in particular A2 (Fig. 1,
Additional file 1: Table S1). In a fourth step, the appropriate
category and subcategory were selected, preferring the
strongest causal explanation of the condition and the most
conclusive supporting evidence taking into account the
categorization rules shown in Table 1. A total of 791 chil-
dren of 2322 children in the KLR qualified for childhood
DPLD and were further categorized into one of the 12
DPLD categories (Fig. 1, Additional file 1: Table S1) and the
respective subcategories.
Workflow for re-rating of selected DPLD cases retrieved
from the KLR
The validity and observer-dependency was tested in 2012
using a systematic sample of 100 DPLD cases from the co-
hort of 791 children previously categorized according to the
KLR algorithm. 100 cases were selected randomly and in
proportion to their frequency in the KLR categories. All 100
cases were pseudonymized for blinded and independent
re-categorization by two pediatric pneumologists, familiar
with the KLR categorization system (Fig. 1, red lowever
part, Additional file 3: Tables S2, Additional file 4: Table S3).
One of the physicians involved in re-rating was already
involved in the initial categorization, the other was an inde-
pendent physician. A final working diagnosis was newly
established by each re-rater and allocated in the KLR
categorization system, again according to the rules indicated
in Table 1 and the workflow detailed in Additional file 2:
Figure S1, red part. As re-rating of the categorization was
the goal of the study the initial categorization obtained
during routine work-flow was set as the correct one. The
overall frequencies of diagnostics available for the establish-
ment of the final working diagnosis, categorization and sub-
categorization are indicated in Additional file 5: Table S4.
Ethics Statement
All participants gave their written informed consent to par-
ticipate in the KLR consultation and diagnosis program.
The retrospective analysis of the data was approved by the
institutional review board (EK 026–06). Prospective collec-
tion and analysis of data was approved in the GOLD.net
project (EK 257–10), and analysis was performed under the
project FP7-305653-chILD-EU (EK 111–13).
Results
Of 2322 children referred to the KLR between 1997 and
2012, 861 were related to DPLD and included into this co-
hort. Subjects with insufficient information were excluded.
791 remaining subjects were assigned to the 12 DPLD
categories (Fig. 1). Of these subjects 55 % were male; their
age at presentation was 4.2 ± 5.5 years (median 1.0 years,
range 0 to 20). 549 subjects had a lung disease manifesting
primarily in infancy, of which the largest number (294) was
assigned to the category A4 (DPLD–related to alveolar sur-
factant region) (Fig. 1).
Re-categorization of 100 cases was in agreement with
the first allocation in more than 80 % (Table 2). Analysis
of deviation in allocation showed that four kinds of allo-
cation mistakes were made (Table 2): (1) one source for
error was a lack of appreciation of all details available in
the medical records; most of these mistakes were associ-
ated with wrong allocation of subcategories. (2) a second
rater-related source of error was too little knowledge of
and erroneous application of the categorization rules.
For example, chromosomal abnormalities are listed as
an independent category in A2 because they are present
at birth and mainly manifest in infancy, and not in B1,
i.e. related to systemic disease processes. (3) For some
cases previously categorized, the re-rater decided that
data was insufficient. In one case for instance, clinical
and radiological data was available, however no genetic
or histologic information. Information on low levels of
Table 1 Rules for allocating a “final working diagnosis” to the disease categories and subcategories (Continued)
(b) the overall better proof, even if less specific - BPD-cLDI is preferred over pulmonary hypoplasia as the latter can
reliably only be assessed by radial counting of pathology specimens or
experimentally by using novel imaging techniques not routinely available
Abbreviations: ABCA3, ATP-binding cassette sub-family A member 3, BAL bronchoalveolar lavage, BPD-cLDI bronchopulmonary dysplasia - chronic lung disease of
infancy, DPLD diffuse parenchymal lung disease, NEHI Neuroendocrine cell hyperplasia of infancy, NSIP non-specific interstitial pneumonitis, SFTPC surfactant
protein C, TTF1 thyroid transcription factor 1
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hydrophobic surfactant protein content of BAL was not
judged to be helpful (4).
Lastly, shortcomings of the categorization system itself
lead to non-correct categorization: main deficits of the
categorization system were observed for the differentiation
of chronic tachypnea of infancy (A3), and for diseases in-
volving the parenchyma but also or primarily the peripheral
airways. The latter, such as post-infectious obliterative
bronchiolitis and Mac-Leod-Swyer-James-Syndrome, both
for immune-competent and immune-compromised hosts,
were frequently categorized as airway disorders and not as
DPLD. The former, i.e. infants with tachypnea were identi-
fied as neuroendocrine cell hyperplasia, even if there was
no biopsy available. A comprehensive list of erroneous
classification is displayed in Additional files 3 and 4:
Tables S2, S3.
Discussion
Here we describe an algorithm to categorize children
with DPLD; we defined and assessed rules for
categorization and suggest a tool for establishing large
cohorts of consistently categorized subjects with rare
pulmonary diseases. We thus provide an important
basis for the development of consensus-based, inter-
national guidelines for categorization and management
of pediatric DPLD. Consistent categorization is indis-
pensable for handling individual cases in registries and
biobanks appropriately. It allows to combine or split
diagnosis groups and to compare subcategories and cat-
egories. A consistent categorization system is the basis
for future adjustments, such as the inclusion of new
molecular disease entities or of novel diagnostic
methods. A specific working diagnosis may change over
time or knowledge may evolve on a particular subject,
however, the allocation rules should not change, repre-
senting an important constant term.
In this study, several important barriers to a consistent
categorization of rare lung diseases were identified. It was
shown that consistent categorization needs to be repeat-
edly practiced especially for the use in large registers. Con-
tinuous evaluation of the categorization process within a
register will be an important element of quality control.
Lack of sufficient data in a case is a common problem
in clinical practice, hindering the establishment of a cor-
rect diagnosis. Data may be insufficient for many reasons,
such as high costs for diagnostic testing, invasiveness of
tests (e.g. lung biopsy), missing data or poor quality of the
data (e.g. incomplete history, CT scans performed in in-
fants with improper technique). The problem of insuffi-
cient data should not distract from making a diagnosis.
Appreciating all information and details available will yield
a final working diagnosis, which should be clearly indi-
cated. Even if the diagnosis leaves open questions e.g.
“unclear RDS in the mature neonate”, these cases must
nevertheless be categorized. For this purpose the cate-
gories Ax, Ay, Bx were created (Fig. 1, Additional file 1:
Table S1). The cases in these categories can (and must) be
systematically revisited and if more information becomes
available, should be allocated into more specific categories.
These patients can furthermore be included into non-
hypothesis based screening projects, like exome sequen-
cing or disease marker identification projects, with the
aim to identify previously unknown disease causes or to
determine disease activity.
Any classification system is continuously evolving. In-
creasing knowledge on molecular disease mechanisms
allows the definition of new entities, which must be eas-
ily accommodated in the categorization system, as is the
case for the current system.
It is furthermore essential to continuously take note of
potential areas of uncertainty within the system and to
clarify these: there are for example entities for which no
precise diagnostic criteria are available, such as the dif-
ferentiation of infants with chronic tachypnea in the ab-
sence of a lung biopsy (See examples in Additional file 3:
Table S2). Another area which needs clarification is the
categorization of diffuse parenchymal diseases which
also involve the distal airways. These patients overlap
with those presenting primarily as obstructive airway
diseases, but cannot merely be classified as such, be-
cause the remodeling of the lung tissue component is
dominant. A precise definition of all subcategories is not
yet available but will be significant to be developed as
“gold-standard”.
Lastly, a rating of the confidence level of the quality of
the data used for establishing the working diagnosis for
the individual cases would be a valuable additional indi-
cator and is desirable to be established in the future.
Table 2 Results of blinded re-rating of 100 subjects with pediatric
DPLD by two independent raters and reasons for incorrect rating
(see individual values in Additional file 3: Table S2)
Blinded rater 1 Blinded rater 2
Category Subcategory Category Subcategory
Correct categorization 80 82 92 84
Non-correct
categorization
20 18 8 16
1 Reports not
appreciated/read
in detail (= true
mistake of rater)




3 4 2 4
3 Insufficient data
on case
8 0 2 2
4 Deficit of the
classification system
4 6 2 4
Data are absolute numbers (total n = 100) or %
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Using a clinically oriented categorization system such
as the one presented here has the advantage that differ-
ent registries or studies using the same definitions and
rules may be compared or combined for analysis. Con-
sistent application of a clinically oriented categorization
system is prerequisite for the establishment of urgently
needed larger cohorts of patients with rare pediatric lung
diseases.
Conclusions
We present hands-on rules for the categorization of all
pediatric DPLD, independent of the presence or absence
of a lung biopsy or the quality of diagnostic data. We
empirically identify pitfalls of categorization and suggest
solutions for improvement with the aim to provide the
basis for the development of consensus-based, inter-
national guidelines for the categorization and manage-
ment of pediatric DPLD.
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